Susquehanna Advisors Group Inc. Buys 102,556 Shares of The Chemours Company $CC

Susquehanna Advisors Group Inc. increased its position in shares of The Chemours Company (NYSE:CC) by 74.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 241,016 shares of the specialty chemicals company’s stock after purchasing an additional 102,556 shares during the quarter. Susquehanna Advisors Group Inc. owned 0.16% of Chemours worth $4,946,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Atlas Capital Advisors Inc. acquired a new stake in Chemours in the fourth quarter valued at about $26,000. Aster Capital Management DIFC Ltd acquired a new position in Chemours during the fourth quarter worth about $28,000. Covestor Ltd raised its stake in Chemours by 204.7% during the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock worth $31,000 after acquiring an additional 1,748 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of Chemours in the fourth quarter worth about $31,000. Finally, Rothschild Investment LLC lifted its holdings in shares of Chemours by 87.0% in the fourth quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock worth $32,000 after acquiring an additional 1,255 shares during the last quarter. 76.26% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CC. Mizuho set a $22.00 price objective on Chemours in a research note on Wednesday, August 5th. Alembic Global Advisors reiterated an “overweight” rating and set a $30.00 target price on shares of Chemours in a research report on Wednesday, May 13th. Weiss Ratings lowered shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, August 6th. Royal Bank Of Canada decreased their price target on shares of Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.10.

Chemours Stock Performance

CC stock opened at $15.64 on Monday. The stock has a 50-day moving average price of $17.39 and a 200-day moving average price of $19.97. The Chemours Company has a 1-year low of $10.44 and a 1-year high of $28.67. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The firm has a market cap of $2.35 billion, a PE ratio of -8.19 and a beta of 1.43.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the previous year, the company earned ($2.54) EPS. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. As a group, equities research analysts expect that The Chemours Company will post 0.87 earnings per share for the current year.

Chemours Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Friday, August 14th. Chemours’s dividend payout ratio is presently -18.32%.

Insiders Place Their Bets

In other news, insider Calderon Gerardo Familiar acquired 1,935 shares of Chemours stock in a transaction on Wednesday, August 12th. The stock was purchased at an average price of $15.53 per share, with a total value of $30,050.55. Following the completion of the purchase, the insider owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. The trade was a 3.42% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Denise Dignam purchased 3,378 shares of Chemours stock in a transaction that occurred on Tuesday, August 11th. The stock was acquired at an average cost of $14.95 per share, with a total value of $50,501.10. Following the transaction, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. This trade represents a 1.00% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 8,663 shares of company stock worth $130,601. Corporate insiders own 0.85% of the company’s stock.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.